ECM
SPRY icon

EMC Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

EMC Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,224
Closed -$48K – 349
2021
Q4 		$48K Hold
7,224
– – 0.03% 102
2021
Q3 		$62K Buy
+7,224
New +$178K 0.03% 108

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EMC Capital Management's SPRY Position: Q1 2022 in Review

EMC Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 7,224 shares — an estimated $48K sold.

EMC Capital Management first reported a position in SPRY in Q3 2021 and held it in 2 quarters. The position peaked at $62K in Q3 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

  • EMC Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • EMC Capital Management sold 7,224 ARS Pharmaceuticals shares in Q1 2022, an estimated $48K.
  • EMC Capital Management first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • EMC Capital Management's ARS Pharmaceuticals position peaked at $62K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on EMC Capital Management's 13F filing for Q1 2022, filed 16 May 2022.